Last reviewed · How we verify
Sulfauridin (SULFADICRAMIDE)
Sulfadicroamide (Sulfauridin) is a marketed antibiotic that inhibits bacterial folic acid synthesis, currently holding an unspecified market position with key patent expiry in 2028. Its mechanism of action provides a strong competitive advantage by effectively targeting bacterial growth and survival, distinguishing it from other sulfa drugs. However, the primary risk lies in the competitive landscape, with multiple off-patent same-class drugs such as sulfamethizole, sulfafurazole, sulfacetamide, and sulfaphenazole already available, potentially eroding market share.
At a glance
| Generic name | SULFADICRAMIDE |
|---|---|
| Drug class | sulfadicramide |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfauridin CI brief — competitive landscape report
- Sulfauridin updates RSS · CI watch RSS